Factor replacement therapy in haemophilia - Are there models for developing countries?

Haemophilia

Volumn 9, Issue 4, 2003, Pages 391-396

  Srivastava, A ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Country; Developing; Factor; Haemophilia; Models; Replacement

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR CONCENTRATE; FRESH FROZEN PLASMA;

ARTICLE; BLOOD BANK; COST EFFECTIVENESS ANALYSIS; CRYOPRECIPITATE; DEVELOPING COUNTRY; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; ECONOMIC ASPECT; HEALTH CARE ACCESS; HEMARTHROSIS; HEMOPHILIA; HUMAN; JOINT FUNCTION; LONG TERM CARE; MEDICAL DOCUMENTATION; MUSCULOSKELETAL FUNCTION; PHYSICAL DISABILITY; PLASMA; PRIORITY JOURNAL; SUBSTITUTION THERAPY; TREATMENT OUTCOME; VIRUS INACTIVATION;

EID: 0038487187     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2003.00766.x     Document Type: Article

References (28)

1. Pool IG, Harshgold EJ, Pappenhagen AB. High potency antihaemophilic factor concentrates prepared from cryoglobulin precipitate. Nature 1964; 203: 312.
2. Kasper CK, Dietrich SL, Rapaport SI. Haemophilia prophylaxis with factor VIII concentrate. Arch Int Med 1970; 125: 1004-9.
3. Nilsson IM, Berntorp E, Lofquist T et al. Twenty five years experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 25-32.
4. Aledort LM, Haschmayer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor VIII deficient haemophiliacs. J Int Med 1994; 236: 391-9.
5. Mannucci PM. The choice of plasma-derived clotting factor concentrates. Bailliere's Clin Haematol 1996; 9: 273-90.
6. Cusher JM. Recombinant clotting factor concentrates. Bailliere's Clin Haematol 1996; 9: 291-303.
7. Tietel JM. Safety of coagulation factor concentrates. Haemophilia 1998; 4: 393-401.
8. Bohn RL, Avora J, Glynn RJ et al. Prophylactic use of factor VIII: an economic evaluation. Thromb Haemost 1998; 79: 932-7.
9. Srivastava A. Delivery of haemophilia care in the developing world. Haemophilia 1998; 4 (Suppl. 2): 33-40.
10. Srivastava A. Factor replacement for haemophilia: should cryoprecipitate be used. Haemophilia 1999; 5: 301-5.
11. Astermark J, Petrini P, Tengborn L et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
12. United Nations Organizations. Trends and policies in the world economy. World Economic and Social Review UNO, 1997.
13. Fisher K, Van Der Bom JG, Manser-Bunschofen EP et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumptions and arthropathy. Haemophilia 2001; 7: 446-52.
14. Srivastava A, Chuansumrit A, Chandy M, Duraiswamy G, Karabus C. Management of haemophilia in the developing world. Haemophilia 1998; 4: 474-80.
15. Richard KA. Guidelines for therapy and optimal doses of coagulation factor for treatment of bleeding and surgery in haemophilia. Haemophilia 1995; 1 (Suppl. 1): 8-13.
16. Martinowitz U, Schulman S, Gital S et al. Adjusted dose continuous infusion of factor concentrates in patients with haemophiia A. Br J Haematol 1992; 2: 729-34.
17. Bhushan V, Chandy M, Khanduri U et al. Surgery in patients with congenital coagulation disorder. Nat Med J India 1994; 7: 8-12.
18. Srivastava A, Chandy M, Sunderaraj GD et al. Low dose intermittent factor replacement for post-operative haemostasis in haemophilia. Haemophilia 1998; 4: 799-801.
19. Ghosk K, Jijina F, Pathare AV, Mohanty D. Surgery in haemophilia: experience from a centre in India. Haemophilia 1998; 4: 94-7.
20. Srivastava A, Mathews V, Lee V et al. Continuous infusion of low doses of factors for post-operative hemostasis in haemophilia. Thromb Haemost 2001; (Abstract no. 2569).
21. Kasper CK, Boylen AC, Ewing NP. Hematologic management of haemophilia A for surgery. JAMA 1985; 253: 1279-83.
22. Brettler DB. Inhibitor in congenital haemophilia. Bailliere's Clin Haematol 1996; 9: 319-30.
23. Di Michele D. Immune tolerance: a synopsis of the international experience. Haemophilia 1998; 4: 368-73.
24. Kroner BL. Comparison of the international immune tolerance registry and the North American immune tolerance registry. Vox Sang 1999; 77 (Suppl 1): 33-7.
25. Kavakli K, Gringeri A, Bader R et al. Inhibitor development and substitution therapy in a developing country: Turkey. Haemophilia 1998; 4: 104-8.
26. Chuansumrit A, Pakakasama S, Kuhathong R, Chantanakajornfung A, Hathirat P. Immune tolerance in a patient with haemophilia A and high titre inhibitors using locally prepared lyophilized cryoprecipitate. Haemophilia 2000; 6: 523-5.
27. Srivastava A. Choice of factor concentrates for haemophilia: a developing world perspective. Haemophilia 2001; 7: 117-22.
28. Bird A, Isarangkura P, Almagro D, Gonzaga A, Srivastava A. Factor concentrates for haemophilia in the developing world. Haemophilia 1998; 4: 481-5.